AOD-9604 vs Tesamorelin: hGH Fragment versus GHRH Analog Comparison

AOD-9604 and tesamorelin are both discussed in fat-loss research, but they are not the same pharmacologic class.

AOD-9604 is a synthetic analog of the C-terminal lipolytic domain of human GH. Ng et al. treated obese Zucker rats with oral AOD9604 500 µg/kg daily for 19 days: body-weight gain was 15.8 ± 0.6 g versus 35.6 ± 0.8 g in controls, adipose tissue showed increased lipolytic activity, and euglycemic clamps did not show the insulin-sensitivity impairment seen with chronic intact hGH (PMID: 11146367). Heffernan et al. then showed that both hGH and AOD9604 reduced body weight and fat in obese mice and increased β3-adrenergic receptor RNA, but that lipolytic actions were not mediated directly through the β3-AR. Chronic treatment in β3-AR knockout mice failed to reproduce the body-weight and lipolysis changes seen in wild-type mice, though an acute experiment still increased energy expenditure and fat oxidation in knockouts (PMID: 11713213). In short, the chronic fat-loss signal in mice needs an intact β3-AR pathway, without AOD9604 acting as a simple direct β3-AR agonist.

Tesamorelin is a GHRH analog. It stimulates pituitary GH release. The VAT reduction in HIV lipodystrophy trials is a GH-axis, whole-body effect measured on CT, not a fragment acting on adipocyte lipolysis in isolation (PMID: 18057338, PMID: 20554713).

AOD-9604 is not a GHRH analog, and tesamorelin is not an hGH 176-191 fragment.

Tesamorelin

Pooled Phase 3 (n=806): tesamorelin 2 mg daily for 26 weeks reduced VAT 15.4% versus placebo, preserved abdominal SAT, lowered triglycerides (treatment effect −12.3%), and raised IGF-I (PMID: 20554713). The NEJM trial (n=412) reported VAT −15.2% versus +5.0% placebo (PMID: 18057338). Stanley et al. (n=50) added a liver-fat reduction (median lipid-to-water percentage −2.0% versus +0.9% placebo, P=0.003) (PMID: 25038357). These are human, imaging-based RCTs in HIV-associated abdominal fat accumulation.

AOD-9604

Published efficacy is preclinical. Ng 2000 and Heffernan 2001 are rodent metabolic studies (PMID: 11146367, PMID: 11713213). Kwon and Park injected AOD9604 weekly into collagenase-induced osteoarthritic rabbit knees, with or without hyaluronic acid, and reported better morphological and histopathological cartilage scores and a shorter lameness period, especially for the combination, versus saline (PMID: 26275694). That work is a rabbit OA model, not a human osteoarthritis or obesity trial.

Wilding’s 2004 development review said Metabolic was developing AOD-9604 for obesity and that Phase IIa trials were underway by February 2002 (PMID: 15134286). The abstract has no Phase IIa or IIb efficacy numbers. A PubMed search for AOD9604 and AOD-9604 on 27 August 2026 did not return a randomized human obesity trial, so press-recap enrollment and kilogram-change figures are left out.

Tesamorelin. Pooled Phase 3: generally well tolerated; no clinically meaningful glucose differences at weeks 26 and 52 despite IGF-I elevation (PMID: 20554713). NEJM: similar overall adverse-event rates, more withdrawals for adverse events on tesamorelin (PMID: 18057338). Stanley: transient fasting-glucose rise at 2 weeks, not significant at 6 months (PMID: 25038357). These data are from the HIV-lipodystrophy 2 mg daily program.

AOD-9604. Ng reported no insulin-sensitivity impairment in Zucker rats relative to intact hGH (PMID: 11146367). Kwon reported a rabbit intra-articular series, not a human safety database (PMID: 26275694). There is no PubMed-indexed randomized human safety trial among the citations above. Missing human RCTs do not establish safety.

Tesamorelin is FDA-approved (Egrifta/Egrifta SV) for excess abdominal fat in HIV-associated lipodystrophy. That is a labeled drug indication, not a general weight-loss license.

AOD-9604 has no drug approval in any country. GRAS status, where it applies, is a food-ingredient category and does not show anti-obesity efficacy. Wilding 2004 describes an obesity development program that, in this PubMed search, never produced an indexed pivotal trial (PMID: 15134286).

For human visceral-fat evidence, tesamorelin is the studied drug: a defined HIV-lipodystrophy population, with CT VAT as the Phase 3 endpoint. That is not a head-to-head win against AOD-9604 in a trial that was never run, and it is not a general obesity ranking.

AOD-9604 has rodent lipolysis and weight-gain data and a rabbit cartilage model. PubMed does not index a human obesity RCT. The cartilage findings are preclinical.

Human AOD-9604 efficacy and safety at any metabolic indication remain unpublished in indexed trials. So does any tesamorelin versus AOD-9604 comparison, and so does translation of the rodent lipolysis signal.